Could a home ultrasound device transform gestational diabetes care?
NCT ID NCT07158970
First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study will test whether giving women with gestational diabetes a home ultrasound device, guided remotely by a doctor, improves their satisfaction and health outcomes compared to standard care. About 90 participants will use the device for fetal checks from home. The goal is to see if this approach makes care more convenient and effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Pulsenmore home ultrasound device
- What this could lead to
- If successful, this could make pregnancy monitoring more convenient and satisfying for women with gestational diabetes, potentially reducing clinic visits and healthcare costs.
- What could go wrong
- This is a small, early-stage study (90 participants) that hasn't started yet. The device may not improve outcomes or satisfaction significantly, and results may not apply to non-Hebrew speakers or those with multiple pregnancies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 51 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Singleton pregnancy * GDM diagnosed by OGTT or glucose monitoring * Hebrew speaking * Compatible cellphone Exclusion Criteria: * Pregestational diabetes * Fetal anomalies/genetic abnormalities * Multifetal pregnancy * Late GDM diagnosis (after 34 weeks)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gestational diabetes mellitus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Edith Wolfson Medical Center
RECRUITINGH̱olon, Central District, 5834468, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a hormone blocking drug reveal why gestational diabetes happens?
- Can weightlifting beat cardio for blood sugar in pregnancy?
- Can a phone app tame gestational diabetes?
- Five minutes a day: breathing training may tame pregnancy blood pressure
- Birth cohort study aims to uncover roots of Youth-Onset type 2 diabetes in indigenous communities
- Simple alerts may keep At-Risk moms healthy after birth